MELK and adrenal cortex carcinoma: Quantitative high-throughput drug screening on ACC cells in a preclinical study has revealed a novel combination of CDK inhibitor and maternal embryonic leucine zipper kinase (MELK) inhibitor, which can effectively target a variety of molecules related to ACC aggressiveness (56).